MedTrace Logo

Dexmedetomidine for LISA Procedure in Preterm Infants

NCT04820101 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-04-29

No results posted yet for this study

Summary

The investigators aim to evaluate: the effectiveness of dexmedetomidine for analgesia and sedation during LISA procedure, without compromising the respiratory drive; the safety of this drug on the preterm infant in a pilot study.

Conditions

  • RDS

Interventions

DRUG

Dexmedetomidine

administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure

Sponsors & Collaborators

  • University of Padova

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
26 Weeks
Max Age
36 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2023-04-01
Completion
2023-04-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820101 on ClinicalTrials.gov